Shandong Henry Pharmaceutical Technology

Shandong Henry Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, specializing in the research and development of innovative small molecule drugs. The company's primary focus is on gastrointestinal disorders and pain management, with a lead candidate, H008, currently in late-stage clinical trials. H008 is a potassium-competitive acid blocker (P-CAB) designed to treat acid-related diseases such as gastroesophageal reflux disease and peptic ulcers. Beyond gastroenterology, the company is advancing a pipeline of novel analgesics targeting specific sodium channels to provide effective pain relief with reduced side effects. Shandong Henry Pharmaceutical maintains a strong R&D infrastructure in Jinan to support its goal of delivering high-quality, affordable innovative medicines to the global market.